AE-941. Oncolytic antipsoriatic treatment of age-related macular degeneration angiogenesis inhibitor

Drugs of the Future

Volumn 25, Issue 6, 2000, Pages 551-557

  Sorbera, L A ^a   Castaner R M ^a   Leeson, P A ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; ANTIPSORIASIS AGENT; CETUXIMAB; CILENGITIDE; COMBRESTATIN A4 PHOSPHATE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GFB 111; HALOFUGINONE; HYB 165; IM 862; LENALIDOMIDE; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; PI 88; REBIMASTAT; RO 317453; S 3304; SOLIMASTAT; SQUALAMINE; THALIDOMIDE; TROPONIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; ZD 6476;

ANGIOGENESIS; CANCER INHIBITION; CARTILAGE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PSORIASIS; RETINA MACULA DEGENERATION; REVIEW; SHARK;

EID: 0343517634     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.06.569306     Document Type: Review

References (26)

1. Dupont, E., Savard, P.E., Jourdain, C., Juneau, C., Thibodeau, A., Ross, N., Marenus, K., Maes, D.H., Pelletier, G., Sauder, D.N. Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis. J Cutan Med Surg 1998, 2: 146-52.
2. Dupont, E., Brazeau, P., Juneau, C. (Les Laboratoires AEterna Inc.). Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof. CA 2188793, CA 2212010, US 5618925, WO 9532722, WO 9623512.
3. Dupont, E., Brazeau, P., Juneau, C., Maes, D.H., Marenus, K. (Les Laboratoires AEterna Inc.). Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compsns. thereof. CA 2236021, US 6025334, WO 9716197.
4. Dupont, E. (Les Laboratoires AEterna Inc.). Compsns. for treating tumors containing shark cartilage extracts and anti-neoplastic agents. CA 2281570, WO 9840088.
5. Dupont, E., Brazeau, P., Juneau, C. (Les Laboratoires AEterna Inc.). Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression: Process of making thereof. US 5985839.
6. Dupont, E., Brazeau, P., Juneau, C., Maes, D.H., Marenus, K. (Les Laboratoires AEterna Inc.). Methods of using extracts of shark cartilage. US 6028118.
7. Dupont, E., Lachance, Y., Lessard, D., Auger, S. (Les Laboratoires AEterna Inc.). Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof. WO 0004910.
8. Batist, G. AE-941, an inhibitor of angiogenesis: An update of clinical trials in oncology. 17th Chemother Found Symp. Innovative Cancer Chemother Tomorrow (Nov 3-6, New York) 1999, Abst 37.
9. Dupont, E., Alaoui-Jamali, M., Wang, T., Doillon, C., Ross, N., Thibodeau, A., Alpert, L., Savard, P., Falardeau, P. Angiostatic and antitumoral activity of AE-941 (Neovastat®), a molecular fraction derived from shark cartilage. Proc Amer Assoc Cancer Res 1997, 38: Abst 1530.
10. Blasecki, J., Alaoui-Jamali, M., Wang, T., Doillon, C., Thibodeau, A., Savard, P., Falardeau, P., Dupont, E. Oral administration of Neovastat(R) inhibits tumor progression in animal models of progressive tumor growth and metastasis. Int J Oncol 1997, 11(Suppl.): Abst 314.
11. Evans, W.K., Latreille, J., Batist, G., Falardeau, P., Champagne, P., Rivière, M., Dupont, E. AE-941, an inhibitor of angiogenesis: Rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (NSCLC). Eur J Cancer 1999, 35(Suppl. 4): Abst 992.
12. Béliveau, R., Delbecchi, L., Beaulieu, E., Kachra, Z. AE-941: A potent inhibitor of matrix metalloproteinase. Proc Amer Assoc Cancer Res 1999, 40: Abst 3026.
13. Beliveau, R., Sirois, P., Tranqui, L., Baffert, F., Dimitriadou, V., Pepin, M.-C., Sirois, M.G., Poyet, P., Falardeau, P., Dupont, E. AE-941: A potent inhibitor of matrix metalloproteinase. Proc Amer Assoc Cancer Res 2000, 41: Abst 3617.
14. Sirois, M.G. AE-941, a new and specific VEGF antagonist? Proc Amer Assoc Cancer Res 1999, 40: Abst 1517.
15. Rivière, M., Latreille, J., Falardeau, P., Batist, G., Dupont, E. AE-941 (Neovastat), an inhibitor of angiogenesis: Phase I/II cancer clinical trial results. Cancer Invest 1999, 17(Suppl. 1): Abst 16.
16. Jamali, M.-A., Rivière, M., Falardeau, P., Thibodeau, A., Dimitriadou, V., Dupont, E. Effect of AE-941 (Neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention and survival. J Clin Pharmacol 1998, 38(9): Abst 577.
17. Rivière, M., Alaoui-Jamali, M., Falardeau, P., Blasecki, J., Dupont, E. Neovastat: An inhibitor of angiogenesis with anti-cancer activity. Proc Amer Assoc Cancer Res 1998, 39: Abst 317.
18. Zhuang, L., Wang, B., Shivji, G.M., Bordelieu, R., Savard, P., Falideau, P., Dupont, E., Sauder, D.N. AE-941, a novel inhibitor of angiogenesis has significant anti-inflammatory effect on contact hypersensitivity. J Invest Dermatol 1997, 108(4): Abst 575.
19. Latreille, J., Laberge, F., Rivière, M., Falardeau, P., Champagne, P., Croteau, D., Dupont, E., Levinton, C. Phase I/II clinical trials of escalating dose of AE-941, an inhibitor of angiogenesis, in patients with refractory lung cancer. Proc Amer Assoc Cancer Res 1999, 40: Abst 611.
20. Evans, W.K., Latreille, J., Batist, G., Falardeau, P., Champagne, P., Dupont, E. AE-941, an inhibitor of angiogenesis: Rationale for a phase III study of AE-941 in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC). AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 16-19, Washington DC) 1999, Abst 221.
21. Evans, W.K., Latreille, J., Batist, G., Patel, D., Falardeau, P., Croteau, D., Riviere, M. AE-941, an inhibitor ol angiogenesis: Rationale for development in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999, 18: Abst 1938.
22. AEterna presents promising phase I data for AE-941 in AMD. DailyDrugNews.com (Daily Essentials) Dec 13, 1999.
23. Miller, D.R., Granick, J.L., Stark, J.J., Anderson, G.T. Phase I/II trial of the safety and efi cacy of shark cartilage in the treatment of advanced cancers. Proc Am Soc Clin Oncol 1997, 16: Abst 173.
24. AEterna's AE-941/Psovascar shows positive results in phase I/II trial in psoriasis. DailyDrugNews.com (Daily Essentials) March 26, 1999.
25. AEterna cleared to commence phase III trial of AE-941 for treatment of kidney cancer. DailyDrugNews.com (Daily Essentials) March 13, 2000.
26. AEterna Web Site, Feb 17, 2000.